Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Andrew Bottomley, Daniil Stroyakovskiy, Ragini R. Kudchadkar et al.|The Lancet Oncology|2021

Cited by 72